Transient 5-(4-phenylbutoxy)psoralen (PAP-1) treatment dissociates developing pathologies in autoimmune optic neuritis into two distinct pathology profiles

Journal of Neuroscience Research

Volumn 86, Issue 9, 2008, Pages 2111-2124

  Stokely, Martha E ^a,b   Garg, Puja ^a   Bhat, Manzoor A ^c   Koulen, Peter ^a,b,d  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b UNTHSC   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Department of Pharmacology and Neuroscience ^*

Author keywords

Autoimmune optic neuritis; Experimental; Myelinated axon pathology

Indexed keywords

5 (4 PHENYLBUTOXY)PSORALEN; IMMUNOGLOBULIN; MYELIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PSORALEN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AXONAL INJURY; B LYMPHOCYTE; BROWN NORWAY RAT; CELL INFILTRATION; CONTROLLED STUDY; DISEASE MODEL; EFFECTOR CELL; FEMALE; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; INFLAMMATION; MICROFLUOROMETRY; MULTIPLE SCLEROSIS; NERVE FIBER TRANSPORT; NONHUMAN; OPTIC NERVE; OPTIC NEURITIS; PRIORITY JOURNAL; RAT;

ANIMALS; AUTOIMMUNE DISEASES; ENDOTHELIN-1; FEMALE; FICUSIN; INFLAMMATION; INTERLEUKIN-1; MYELIN-ASSOCIATED GLYCOPROTEIN; OPTIC NEURITIS; RATS; RATS, INBRED BN;

EID: 48249157929     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21645     Document Type: Article

References (110)

1. Aquino DA, Capello E, Weisstein J, Sanders V, Lopez C, Tourtellotte WW, Brosnan CF, Raine CS, Norton WT. 1997. Multiple sclerosis: altered expression of 70- and 27-kDa heat shock proteins in lesions and myelin. J Neuropathol Exp Neurol 56:664-672.
2. Arata L, Leonardi A. 1988. Oligoclonal and polyclonal synthesis of IgG in the central nervous system: an isoelectric focusing study. Clin Immunol Immunopathol 47:10-18.
3. Barcellos LF, Green AJ, Bucher P, Rimmler JB, Schmidt S, Garcia ME, Lincoln RR, Pericak-Vance MA, Haines JL, Hauser SL, "Multiple Sclerosis Genetics Group." 2002. Genetic basis for clinical expression in multiple sclerosis. Brain 125:150-158.
4. Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M, Bernard D, Cahalan MD, Chandy KG, Beraud E. 2001. Selective blockade of T lymphocyte K channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A 98:13942-13947.
5. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, Andrews BS, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, Knaus HG, Nepom GT, Gutman GA, Calabresi PA, Chandy KG. 2006. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A 103:17414-17419.
6. Bellen HJ, Lu Y, Beckstead R, Bhat MA. 1998. Neurexin IV, caspr and paranodin - novel members of the neurexin family: encounters of axons and glia. Trends Neurosci 21:444-449.
7. Benveniste EN. 1997. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med 75:165-173.
8. Bhat MA, Rios JC, Lu Y, Garcia-Fresco GP, Ching W, St. Martin M, Li J, Einheber S, Chesler M, Rosenbluth J, Salzer JL, Bellen HJ. 2001. Axon-glia interactions and the domain organization of myelinated axons requires neurexin IV/Caspr/paranodin. Neuron 30:369-383.
9. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. 2000. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123:1174-1183.
10. Bjartmar C, Yin X, Trapp BD. 1999. Axonal pathology in myelin disorders. J Neurocytol 28:383-395.
11. Brady ST, Witt AS, Kirkpatrick LL, de Waegh SM, Readhead C, Tu P-H, Lee VM-Y. 1999. Formation of compact myelin is required for maturation of the axonal cytoskeleton. J Neurosci 19:7276-7288.
12. Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD. 2000. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. Neuroscience 20:6404-6412.
13. Charcot M. 1868. Histologie de le sclerose en plaques. Gazette Hopitaux 141:554-558.
14. Chew BH, Weaver DF, Gross PM. 1995. Dose-related potent brain stimulation by the neuropeptide endothelin-1 after intraventricular administration in conscious rats. Pharmacol Biochem Behav 51:37-47.
15. Coleman MP, Adalbert R, Beirowski B. 2005. Neuroprotective strategies in MS: lessons from C57BL/Wld(S) mice. J Neurol Sci 233:133-138.
16. Coman I, Aigrot MS, Seilhean D, Reynolds R, Girault JA, Zalc B, Lubetzki C. 2006. Nodal, paranodal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis. Brain 129:3186-3189.
17. Comi G. 2003. From inflammation to degeneration: the lessons of clinical trials. Neurol Sci 24(Suppl 5):S295-S297.
18. Confavreux C, Vukusic S. 2006. Natural history of multiple sclerosis: a unifying concept. Brain 129:606-616.
19. Confavreux C, Vukusic S, Moreau T, Adeleine P. 2000. Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430-1438.
20. Damjanovich S, Gaspar R, Panyi G. 2004. An alternative to conventional immunosuppression: small-molecule inhibitors of kv1.3 channels. Mol Interv 4:250-254.
21. Dandekar AA, Wu GF, Pewe L, Perlman S. 2001. Axonal damage is T cell mediated and occurs concomitantly with demyelination in mice infected with a neurotropic coronavirus. J Virol 75:6115-6120.
22. de Waegh SM, Lee VM, Brady ST. 1992. Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell 68:451-463.
23. Dello Russo C, Polak PE, Mercado PR, Spagnolo A, Sharp A, Murphy P, Kamal A, Burrows FJ, Fritz LC, Feinstein DL. 2006. The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. J Neurochem 99:1351-1362.
24. DeLuca GC, Williams K, Evangelou N, Ebers GC, Esiri MM. 2006. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 129:1507-1516.
25. Diem R, Hobom M, Maier K, Weissert R, Storch MK, Meyer R, Bähr M. 2003. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci 23:6993-7000.
26. Diem R, Sattler MB, Merkler D, Demmer I, Maier K, Stadelmann C, Ehrenreich H, Bahr M. 2005. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 128:375-385.
27. Doolittle TH, Myers RH, Lehrich JR, Birnbaum G, Sheremata W, Franklin GM, Nelson LM, Hauser SL. 1990. Multiple sclerosis sibling pairs: clustered onset and familial predisposition. Neurology 40:1546-1552.
28. Dubcenco E, Ottaway CA, Chen DL, Baker JP. 2006. Neurological symptoms suggestive of demyelination in Crohn's disease after infliximab therapy. Eur J Gastroenterol Hepatol 18:565-566.
29. Fairweather D, Frisancho-Kiss S, Gatewood S, Njoku D, Steele R, Barrett M, Rose NR. 2004. Mast cells and innate cytokines are associated with susceptibility to autoimmune heart disease following coxsackievirus B3 infection. Autoimmunity 37:131-145.
30. Faivre-Sarrailh C, Banerjee S, Li J, Hortsch M, Laval M, Bhat MA. 2004. Drosophila contactin, a homolog of vertebrate contactin, is required for septate junction organization and paracellular barrier function. Development 131:4931-4942.
31. Ferguson B, Matyszak MK, Esiri MM, Perry VH. 1997. Axonal damage in acute multiple sclerosis lesions. Brain 120:393-399.
32. Fernandes A, Falcao AS, Silva RF, Gordo AC, Gama MJ, Brito MA, Brites D. 2006. Inflammatory signalling pathways involved in astroglial activation by unconjugated bilirubin. J Neurochem 96:1667-1679.
33. Freeman HJ, Flak B. 2005. Demyelination-like syndrome in Crohn's disease after infliximab therapy. Can J Gastroenterol 19:313-316.
34. Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, Lucchinetti C, Wilken J, Karandikar N, Hemmer B, Monson N, De Keyser J, Hartung H, Steinman L, Oksenberg JR, Cree BA, Hauser S, Racke MK. 2005a. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol 62:1345-1356.
35. Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. 2005b. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 4:111-121.
36. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. 2003. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198:267-279.
37. Garcia-Fresco GP, Sousa AD, Pillai AM, Moy SS, Crawley JN, Tessarollo L, Dupree JL, Bhat MA. 2006. Disruption of axo-glial junctions causes cytoskeletal disorganization and degeneration of Purkinje neuron axons. Proc Natl Acad Sci U S A 103:5137-5142.
38. Gélinas DS, Lambermon MH, McLaurin J. 2005. Ciglitazone increases basal cytokine expression in the central nervous system of adult rats. Brain Res 1034:139-146.
39. Ghosh A, Kelly SP, Mathews J, Cooper PN, Macdermott N. 2002. Evaluation of the management of optic neuritis: audit on the neurological and ophthalmological practice in the northwest of England. J Neurol Neurosurg Psychiatry 72:119-121.
40. Gilmore M, Grennan E. 2003. A pilot study of the relationship between multiple sclerosis and the physical environment in northwest Ireland. Environ Geochem Health 25:157-163.
41. Haahr S, Hollsberg P. 2006. Multiple sclerosis is linked to Epstein-Barr virus infection. Rev Med Virol 16:297-310.
42. Haufschild T, Shaw SG, Kesselring J, Flammer J. 2001. Increased endothelin-1 plasma levels in patients with multiple sclerosis. J Neuroophthalmol 21:37-38.
43. Hemmer B, Cepok S, Zhou D, Sommer N. 2004. Multiple sclerosis - a coordinated immune attack across the blood brain barrier. Curr Neurovasc Res 1:141-150.
44. Hobom M, Storch MK, Weissert R, Maier K, Radhakrishnan A, Kramer B, Bahr M, Diem R. 2004. Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol 14:148-157.
45. Hoehn B, Ringer TM, Xu L, Giffard RG, Sapolsky RM, Steinberg GK, Yenari MA. 2001. Overexpression of HSP72 after induction of experimental stroke protects neurons from ischemic damage. J Cereb Blood Flow Metab 21:1303-1309.
46. Howe CL, Mayoral S, Rodriguez M. 2006. Activated microglia stimulate transcriptional changes in primary oligodendrocytes via IL-1beta. Neurobiol Dis 23:731-739.
47. Huang CJ, Nazarian R, Lee J, Zhao PM, Espinosa-Jeffrey A, de Vellis J. 2002. Tumor necrosis factor modulates transcription of myelin basic protein gene through nuclear factor kappa B in a human oligodendroglioma cell line. Int J Dev Neurosci 20:289-296.
48. Ishii Y, Kwong JM, Caprioli J. 2003. Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Invest Ophthalmol Vis Sci 44:1982-1992.
49. Kaether C, Skehel P, Dotti CG. 2000. Axonal membrane proteins are transported in distinct carriers: a two-color video microscopy study in cultured hippocampal neurons. Mol Biol Cell 11:1213-1224.
50. Kawarabayashi T, Shoji M, Yamaguchi H, Tanaka M, Harigaya Y, Ishiguro K, Hirai S. 1993. Amyloid beta protein precursor accumulates in swollen neurites throughout rat brain with aging. Neurosci Lett 153:73-76.
51. Kirkpatrick LL, Brady ST. 1994. Modulation of the axonal microtubule cytoskeleton by myelinating Schwann cells. J Neurosci 14:7440-7450.
52. Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL. 1990. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci U S A 87:1561-1565.
53. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, Linington C, Schmidbauer M, Lassmann H. 2000. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 157: Am J Pathol 2157:2267-2276.
54. Kornek B, Storch MK, Bauer J, Djamshidian A, Weissert R, Wallstroem E, Steffel A, Zimprich F, Olsson T, Linington C, Schmidbauer M, Lassmann H. 2001. Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 124:1114-1124.
55. Kruger PG, Bo L, Myhr KM, Karlsen AE, Taule A, Nyland HI, Mork S. 1990. Mast cells and multiple sclerosis: a light and electron microscopic study of mast cells in multiple sclerosis emphasizing staining procedures. Acta Neurol Scand 81:31-36.
56. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. 2002. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125:2202-2212.
57. Lalive PH, Menge T, Delarasse C, Della Gaspera B, Pham-Dinh D, Villoslada P, von Budingen HC, Genain CP. 2006. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A 103:2280-2285.
58. Lappe-Siefke C, Goebbels S, Gravel M, Nicksch E, Lee J, Braun PE, Griffiths IR, Nave KA. 2003. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet 33:366-374.
59. Lassmann H, Bruck W, Lucchinetti C, Rodriguez M. 1997. Remyelination in multiple sclerosis. Mult Scler 3:133-136.
60. Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. 1999. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457-465.
61. Link H, Huang YM. 2006. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 180:17-28.
62. Lopez Pison J, Garcia Bodega O, Diaz Suarez M, Bajo Delgado AF, Cabrerizo de Diago R, Pena Segura JL. 2004. Episodic disseminated inflammation of the central nervous system. Case mix review over a 13 year period. Rev Neurol 38:405-410.
63. Maggs FG, Palace J. 2004. The pathogenesis of multiple sclerosis: is it really a primary inflammatory process? Mult Scler 10:326-329.
64. Magnano MD, Robinson WH, Genovese MC. 2004. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 22(Suppl 35):S134-S140.
65. Mancardi G, Hart B, Roccatagliata L, Brok H, Giunti D, Bontrop R, Massacesi L, Capello E, Uccelli A. 2001. Demyelination and axonal damage in a non-human primate model of multiple sclerosis. J Neurol Sci 184:41-49.
66. Mancuso R, Delbue S, Borghi E, Pagani E, Calvo MG, Caputo D, Granieri E, Ferrante P. 2007. Increased prevalence of varicella zoster virus DNA in cerebrospinal fluid from patients with multiple sclerosis. J Med Virol 79:192-199.
67. Marrie RA. 2004. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 3:709-718.
68. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN. 2001. Demyelination occurring during antitumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44:2862-2869.
69. Mott RT, Ait-Ghezala G, Town T, Mori T, Vendrame M, Zeng J, Ehrhart J, Mullan M, Tan J. 2004. Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production. Glia 46:369-379.
70. Narayanan S, Francis SJ, Sled JG, Santos AC, Antel S, Levesque I, Brass S, Lapierre Y, Sappey-Marinier D, Pike GB, Arnold DL. 2006. Axonal injury in the cerebral normal-appearing white matter of patients with multiple sclerosis is related to concurrent demyelination in lesions but not to concurrent demyelination in normal-appearing white matter. Neuroimage 29:637-642.
71. Nash PT, Florin TH. 2005. Tumour necrosis factor inhibitors. Med J Aust 183:205-208.
72. Olsson Y. 1974. Mast cells in plaques of multiple sclerosis. Acta Neurol Scand 50:611-618.
73. Paul F, Dorr J, Wurfel J, Vogel HP, Zipp F. 2007. Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 78:198-200.
74. Peterson LK, Fujinami RS. 2007. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol 184:37-44.
75. Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RH, Cuzner ML, Polman CH, Uitdehaag BM, Thompson EJ, Giovannoni G. 2002. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 125:1462-1473.
76. Rasband MN, Tayler J, Kaga Y, Yang Y, Lappe-Siefke C, Nave KA, Bansal R. 2005. CNP is required for maintenance of axon-glia interactions at nodes of Ranvier in the CNS. Glia 50:86-90.
77. Riise T, Moen BE, Kyvik KR. 2002. Organic solvents and the risk of multiple sclerosis. Epidemiology 13:2718-2720.
78. Rizvi SA, Agius MA. 2004. Current approved options for treating patients with multiple sclerosis. Neurology 63(Suppl 6):S2008-S2014.
79. Rizzo JF 3rd, Lessell S. 1988. Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study. Neurology 38:185-190.
80. Robinson WH, Genovese MC, Moreland LW. 2001. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44:1977-1983.
81. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. 2006. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 5:343-354.
82. Saccardi R, Kozak T, Bocelli-Tyndall C, Fassas A, Kazis A, Havrdova E, Carreras E, Saiz A, Lowenberg B, te Boekhorst PA, Gualandio F, Openshaw H, Longo G, Pagliai F, Massacesi L, Deconink E, Ouyang J, Nagore FJ, Besalduch J, Lisukov IA, Bonini A, Merelli E, Slavino S, Gratwohl A, Passweg J, Tyndall A, Steck AJ, Andolina M, Capobianco M, Martin JL, Lugaresi A, Meucci G, Saez RA, Clark RE, Fernandez MN, Fouillard L, Herstenstein B, Koza V, Cocco E, Baurmann H, Mancardi GL, Autoimmune Diseases Working Party of EBMT. 2006. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 12:814-823.
83. Sandler C, Lindstedt KA, Joutsiniemi S, Lappalainen J, Juutilainen T, Kolah J, Kovanen PT, Eklund KK. 2007. Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. Inflamm Res 56:230-239.
84. Sattler MB, Merkler D, Maier K, Stadelmann C, Ehrenreich H, Bahr M, Diem R. 2004. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 11(Suppl 2):S181-S192.
85. Scheinfeld N. 2005. Adalimumab: a review of side effects. Expert Opin Drug Saf 4:637-641.
86. Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hansel W, Wulff H. 2005. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol 68:1254-1270.
87. Sheller RA, Smyers ME, Grossfeld RM, Ballinger ML, Bittner GD. 1998. Heat-shock proteins in axoplasm: high constitutive levels and transfer of inducible isoforms from glia. J Comp Neurol 396:1-11.
88. Shin T, Kang B, Tanuma N, Matsumoto Y, Wie M, Ahn M, Kang J. 2001. Intrathecal administration of endothelin-1 receptor antagonist ameliorates autoimmune encephalomyelitis in Lewis rats. Neuroreport 12:1465-1468.
89. Speciale L, Sarasella M, Ruzzante S, Caputo D, Mancuso R, Calvo MG, Guerini FR, Ferrante P. 2000. Endothelin and nitric oxide levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurovirol 6(Suppl 2):S62-S66.
90. Stokely ME, Hwang S-Y, Hwang J-Y, Fan B, King MA, Inokuchi K, Koulen P. 2006. Polycystin-1 can interact with Homer 1/Vesl-1 in postnatal hippocampal neurons. J Neurosci Res 84:1727-1737.
91. Stokely ME, Bhat MA, Koulen P. 2007. Microfluorimetry defines early axonal damage in a rat model of early optic neuritis: a novel method targeting early CNS autoimmunity. J Neurosci Methods 166:217-228.
92. Storch MK, Steffel A, Brehm U, Weissert R, Wallstrom E, Kerschensteiner M, Olsson T, Linington C, Lassmann H. 1998. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8:681-694.
93. Trotter JL, Wegescheide CL, Garvey WF, Tourtellotte WW. 1984. Studies of myelin proteins in multiple sclerosis brain tissue. Neurochem Res 9:147-152.
94. Tsoi VL, Hill KE, Carlson NG, Warner JE, Rose JW. 2006. Immunohistochemical evidence of inducible nitric oxide synthase and nitrotyrosine in a case of clinically isolated optic neuritis. J Neuroophthalmol 26:87-94.
95. Tsunoda I, Fujinami RS. 2002. Inside-out versus outside-in models for virus induced demyelination: axonal damage triggering demyelination. Springer Semin Immunopathol 24:105-125.
96. Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, Hansel W, Chandy KG. 2004. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol 65:1364-1374.
97. Vukusic S, Confavreux C. 2003. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 206:135-137.
98. Weinshenker BG, Bulman D, Carriere W, Baskerville J, Ebers GC. 1990. A comparison of sporadic and familial multiple sclerosis. Neurology 40:1354-1358.
99. Wolswijk G. 1998. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 18:601-609.
100. Wolswijk G, Balesar R. 2003. Changes in the expression and localization of the paranodal protein Caspr on axons in chronic multiple sclerosis. Brain 126:1638-1649.
101. Woolley DE, Tetlow LC. 2000. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Arthritis Res 2:65-74.
102. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA. 1992. Gamma delta T-cell receptor repertoire in acute multiple sclerosis lesions. Proc Natl Acad Sci U S A 89:4588-4592.
103. + channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. 173:776-786.
104. Yam PS, Takasago T, Dewar D, Graham DI, McCulloch J. 1997. Amyloid precursor protein accumulates in white matter at the margin of a focal ischaemic lesion. Brain Res 760:150-157.
105. Yan J, Harvey BP, Gee RJ, Shlomchik MJ, Mamula MJ. 2006. B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation. J Immunol 177:4481-4487.
106. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. 1988. A novel potent vasoconstrictor peptide produced by vascular endothielial cells. Nature 332:411-415.
107. Yang P, Das PK, Kijlstra A. 2000. Localization and characterization of immunocompetent cells in the human retina. Ocul Immunol Inflamm 8:149-157.
108. Yang YL, Lin MT. 1999. Heat shock protein expression protects against cerebral ischemia and monoamine overload in rat heatstroke. Am J Physiol 276:H1961-H1967.
109. Yenari MA, Fink SL, Sun GH, Chang LK, Patel MK, Kunis DM, Onley D, Ho DY, Sapolsky RM, Steinberg GK. 1998. Gene therapy with HSP72 is neuroprotective in rat models of stroke and epilepsy. Ann Neurol 44:584-591.
110. Zaprianova E, Sotnikov OS, Sergeeva SS, Deleva D, Filchev A, Sultanov B. 2002. Axonal reaction precedes demyelination in experimental models of multiple sclerosis. Morfologiia 122:54-59.